AC regimen: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of cyclophosphamide and doxorubicin used in the adjuvant setting for the treatment of breast cancer; also used for the treatment of recurrent and metastatic breast cancer.<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref> | {{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]] and [[doxorubicin]] used in the adjuvant setting for the treatment of [[breast cancer]]; also used for the treatment of recurrent and [[breast cancer|metastatic breast cancer]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|A|Doxorubicin (Adriamycin)}} | |||
{{chemo|C|Cyclophosphamide}} | |||
==Indications== | ==Indications== | ||
* [[Breast cancer|Recurrent and metastatic breast cancer]]. | * [[Breast cancer|Recurrent and metastatic breast cancer]].<ref name="pmid12181246">{{cite journal| author=Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK et al.| title=A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. | journal=Ann Oncol | year= 2002 | volume= 13 | issue= 8 | pages= 1225-35 | pmid=12181246 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12181246 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 14:02, 11 March 2015
|
WikiDoc Resources for AC regimen |
|
Articles |
|---|
|
Most recent articles on AC regimen |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on AC regimen at Clinical Trials.gov Clinical Trials on AC regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on AC regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on AC regimen Discussion groups on AC regimen Patient Handouts on AC regimen Directions to Hospitals Treating AC regimen Risk calculators and risk factors for AC regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for AC regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: AC; AC Regimen; Adriamycin-Cytoxan Regimen; CA Regimen.
Overview
AC regimen refers to a regimen consisting of cyclophosphamide and doxorubicin used in the adjuvant setting for the treatment of breast cancer; also used for the treatment of recurrent and metastatic breast cancer.[1][2]
Regimen
ADoxorubicin (Adriamycin)
CCyclophosphamide
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK; et al. (2002). "A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer". Ann Oncol. 13 (8): 1225–35. PMID 12181246.